EAM Investors’s Alder Biopharmaceuticals ALDR Stock Holding History

EAM Investors’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-17,562	Closed	-$575K	–	381
2015 Q3	$575K	Sell	17,562 -4,812	-22%	-$205K	0.09%	288
2015 Q2	$1.19M	Sell	22,374 -12,762	-36%	-$464K	0.14%	284
2015 Q1	$1.01M	Sell	35,136 -5,195	-13%	-$143K	0.12%	300
2014 Q4	$1.17M	Buy	+40,331	New	+$724K	0.16%	259

Other funds holding ALDR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

EAM Investors's ALDR Position: Q4 2015 in Review

EAM Investors sold out of Alder Biopharmaceuticals (ALDR) in Q4 2015, closing a stake of 17,562 shares — an estimated $575K sold.

EAM Investors first reported a position in ALDR in Q4 2014 and held it in 4 quarters. The position peaked at $1.19M in Q2 2015. 134 funds tracked by Wall St. Rank hold ALDR as of Q4 2015.

EAM Investors reported no remaining Alder Biopharmaceuticals position as of Q4 2015 after selling out during the quarter.
EAM Investors sold 17,562 Alder Biopharmaceuticals shares in Q4 2015, an estimated $575K.
EAM Investors first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 4 quarters.
EAM Investors's Alder Biopharmaceuticals position peaked at $1.19M in Q2 2015.
134 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2015.

Based on EAM Investors's 13F filing for Q4 2015, filed 5 Feb 2016.